Medical Editor: John P. Cunha, DO, FACOEP
Karbinal ER (carbinoxamine maleate) is an H1 antagonist, a type of antihistamine, used to treat a wide variety of allergic reactions, including seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, allergic skin manifestations of urticaria and angioedema, dermatographism, as therapy for anaphylactic reactions, and to improve the severity of allergic reactions to blood or plasma. Common side effects of Karbinal ER include sleepiness, drowsiness, dizziness, loss of coordination, abdominal pain, upset stomach, constipation, headache, blurred vision, dry mouth/nose/throat, and thickening of mucus.
Karbinal ER is available as an extended-release oral suspension of 4 mg carbinoxamine maleate per 5 mL. Dosage depends of the age of the patient. Karbinal ER may interact with monoamine oxidase inhibitors (MAOIs), alcohol, hypnotics, sedatives, tranquilizers or other substances that suppress the central nervous system. Tell your doctor all medications you use. It is unknown if Karbinal ER causes fetal harm when administered to a pregnant woman or if it can affect a woman's ability to reproduce, and should be given to a pregnant woman only if clearly needed. Karbinal ER should not be given to women who are currently breastfeeding.
Our Karbinal ER (carbinoxamine maleate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Use of Karbinal ER may result in decreased mental alertness with impaired mental or physical abilities [see WARNINGS AND PRECAUTIONS].
The most frequent adverse reactions include: sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial
The following adverse reactions, listed by body system, have been identified in case reports and during the use of carbinoxamine in observational studies. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Central Nervous System: Fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, constipation.
Laboratory: Increase in uric acid levels.
Respiratory: Tightness of chest and wheezing, nasal stuffiness.
Urogenital: Urinary frequency, difficult urination, urinary retention, early menses.
Read the entire FDA prescribing information for Karbinal ER (Carbinoxamine Maleate Extended-Release Oral Suspension)
© Karbinal ER Patient Information is supplied by Cerner Multum, Inc. and Karbinal ER Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.